- Home
- HCAT vs MRSN Comparison
HCAT vs MRSN Comparison
Compare HCAT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCAT | MRSN |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.0M | 138.8M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HCAT | MRSN |
|---|---|---|
| Price | $2.46 | $29.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $4.25 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 578.8K | 114.7K |
| Earning Date | 02-25-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $316,063,000.00 | $33,180,000.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $2.02 | $5.21 |
| 52 Week High | $7.25 | $36.25 |
Technical Indicators
Market Signals| Indicator | HCAT | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 78.89 |
| Support Level | $2.23 | $28.11 |
| Resistance Level | $2.42 | $29.15 |
| Average True Range (ATR) | 0.12 | 0.57 |
| MACD | 0.02 | -0.47 |
| Stochastic Oscillator | 77.42 | 48.68 |
Price Performance
Historical ComparisonAbout HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.